August 19, 2014 | According to a “Globes” report, Israeli stem cell technologies developer Gamida Cell has confirmed reports of signing an investment and options agreement with Novartis Pharma AG. In the terms of the agreement, Novartis will invest $35 million in Gamida Cell and in return will receive 15 percent equity and the option to fully acquire the company. The agreement remains dependent, however, on the achievement of certain milestones, such as the development of NiCord for the treatment of blood cancers like leukemia and lymphoma.
Subscribe to NoCamels weekly newsletter and get our top stories
Related posts
Top Tel Aviv Hospital Using AI In Neurological Therapy
April 18, 2024
Facebook comments